Member Exclusive

Repurposing approved drugs may be beneficial in Leishmaniasis treatment

Researchers at the University of Pennsylvania School of Veterinary Medicine (Philadelphia, PA, USA) have suggested that CD8+ T cell-induced pathology in Leishmaniasis, depends on NLRP3 inflammasome activation and IL-1β signaling. Therefore, inhibiting these with FDA approved drugs may provide therapeutic benefit for Leishmaniasis patients.

Go to the profile of Rachel Coleby
Mar 03, 2017

Please sign in or register for FREE

Register to RxNet

RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.